It takes one to know one

J&J's acquisition of Guidant is uncertain due to the FDA's scrutiny of Guidant's recent quality problems. But Guidant hometown newspaper, the Indianapolis Star points out that J&J's Cordis stent division has had quality problems and FDA scrutiny as well.The Star sees the glass as being half full:

[T]he problems at Cordis give Johnson & Johnson a similar experience as it tries to better understand the issues involved in Indianapolis-based Guidant's regulatory problems.

PS, I misspelled Guidant when I wrote this post. The Blogger spellchecker suggested “goddamned” as a replacement.